Net sales are expected to range between $795 million to $800 million, representing implied growth of 6.6% to 7.2% year-over year on a constant currency basis. These expectations are based on the current foreign currency exchange rates and do not take into account any additional potential exchange rate changes that may occur this year. Non-GAAP adjusted EBITDA is expected to range from $64 million to $69 million. The Company expects to continue to be free cash flow positive for the remainder of 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on OFIX:
- Orthofix Reports Q3 Sales Growth and New Financial Targets
- OFIX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Needham medtech & diagnostics analyst holds analyst/industry conference call
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
